Please ensure Javascript is enabled for purposes of website accessibility

Why Athenex Stock Is Down Today

By Prosper Junior Bakiny – Updated Sep 10, 2020 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a public offering of common stock.

What happened

Shares of Athenex (ATNX 2.44%) were down by 14.3% as of 1:35 p.m. EDT on Thursday, following the company's announcement of the pricing of a public offering of common stock. With Athenex set to dilute existing shareholders, it isn't surprising that investors are selling off shares of the biotech today.

So what

Athenex first announced its intention to raise funds through a public offering on Tuesday. This morning, the company disclosed that it would sell 10 million shares of its common stock at $11 per share. The biotech is also granting underwriters a 30-day option to purchase an additional 1.5 million shares at that price. Athenex expects to collect gross proceeds of $110 million through this transaction. Note that shares ended Wednesday's trading at $13.19. At this writing, they're worth roughly $11.30.

Man holding his head looking at a downward pointing graph on a board.

Image source: Getty Images.

Now what 

Athenex is currently developing an oral version of a chemotherapy drug called paclitaxel, which is typically administered intravenously. The company's oral paclitaxel has delivered positive results in clinical trials, as in treating patients suffering from metastatic breast cancer.

Athenex recently announced that the Food and Drug Administration had accepted its Biologics License Application for oral paclitaxel, and the medicine could earn regulatory approval sometime next year. The biotech says it intends to use the proceeds from this public offering to "label expansion strategies for Oral Paclitaxel," as well as to support other business activities.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athenex, Inc. Stock Quote
Athenex, Inc.
ATNX
$0.27 (2.44%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.